Diagnexia Achieves UKAS Accreditation for ISO 15189, setting a New Benchmark for Safety and Reliability in Digital Pathology
United Kingdom – Diagnexia UK Limited is delighted to announce its recent accreditation to ISO 15189:2022 for their digital pathology service, a globally recognised standard for medical laboratory requirements for quality and competence. Awarded by the United Kingdom Accreditation Service (UKAS), this milestone underscores Diagnexia’s steadfast commitment to safety, quality, and reliability in pathology services.
ISO 15189 accreditation is an international standard that sets requirements for the quality and competence of medical laboratories is a hallmark of technical competence and operational excellence. By adhering to these rigorous standards, Diagnexia ensures that its diagnostic services—from digital slide scanning to pathologist reporting—consistently meet the highest levels of accuracy, reliability, and patient safety. These assurances are critical for customers who entrust Diagnexia with cases that directly impact patient care.
Benefits to Diagnexia Customers
For hospitals, laboratories, and healthcare providers, working with an ISO 15189-accredited partner like Diagnexia brings unparalleled assurance of safety and risk minimisation:
- Minimised Diagnostic Risk: robust quality controls ensure that diagnostic results are accurate, reducing the risk of misdiagnosis or errors in reporting.
- Increased Confidence in Compliance: Customers can rely on Diagnexia to meet strict regulatory standards and data governance requirements, streamlining their own compliance needs.
- Enhanced Patient Outcomes: Reliable and timely diagnostics mean faster, more informed treatment decisions, ultimately improving patient care.
- Trusted Workflow Integration: Diagnexia’s seamless, digitised workflows enhance operational efficiency while maintaining rigorous quality checks at every stage of the diagnostic process.
Prof. Runjan Chetty, Chief Medical Officer of Diagnexia, commented:
“Achieving ISO 15189 accreditation not only validates the precision and reliability of our services but also reinforces our role as a trusted partner in healthcare. For our customers, this certification means they can depend on us to deliver consistent quality and safety, enabling them to focus on patient care with complete confidence.”
By ensuring compliance with ISO 15189, Diagnexia delivers peace of mind to its customers, who often face immense pressure to meet national cancer targets, turnaround times, and staffing shortages. This accreditation guarantees that Diagnexia’s digital services adhere to the most stringent global benchmarks for quality and competence, thereby reducing operational and reputational risks for its clients.
Donal O’Shea, CEO of Diagnexia, added:
“Safety and reliability are at the heart of what we do. With ISO 15189 accreditation, we have further demonstrated our commitment to providing a risk-free, high-quality service to our customers. This is a critical step in redefining how diagnostic services are delivered globally, with safety as our cornerstone.”
A Commitment to Excellence
Diagnexia’s ISO 15189:2022 accreditation involved a comprehensive evaluation of its processes, including case accessioning, slide digitisation, and reporting workflows. This achievement reinforces Diagnexia’s mission to advance digital pathology, providing customers with not just high-quality results but also the confidence that every step of the process is optimised for patient safety and diagnostic certainty.
For more information about Diagnexia and its services, please visit www.diagnexia.com or contact us at info@diagnexia.com.
Diagnexia is a trading name of Diagnexia UK Limited, a company accredited under ISO 15189:2022 for its digital pathology services.
SOURCE: Diagnexia
